Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53
Figure 6
Strategies to achieve synthetic lethality in cells with p53 GOF mutation. (a) KLE endometrial cancer cells, which contain R175H p53 GOF mutation, were treated with increasing concentrations of paclitaxel in the presence of 10 nM LBH589 −/+ BIBF1120 (1 μM) for 72 h, followed by assessment of cell viability by Wst-1 assay. (b) KLE cells were treated with increasing concentrations of paclitaxel −/+ Wee1 inhibitor MK-1775 (125 nM) for 72 h, followed by assessment of cell viability.
